GNH USA

Europe — EMA

Melphalan Sun Pharmaceutical Industries Europe

GNH USA supplies Melphalan Sun Pharmaceutical (Melphalan), an alkylating antineoplastic for myeloma, ovarian cancer, melanoma and leukemia. Request a quote.

Melphalan

Request sourcing

1
Pack/s

What is Melphalan?

Melphalan, the active ingredient in Melphalan Sun Pharmaceutical Industries Europe, is an alkylating agent presented as an intravenous formulation for use in adult patients. It is employed in the treatment of multiple myeloma, ovarian cancer, malignant melanoma and acute leukemia, and is administered under medical supervision in specialized oncology settings.

GNH USA supplies Melphalan Sun Pharmaceutical Industries Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, with capabilities for bulk manufacturing, quality assurance and regulatory support.

What is Melphalan used for?

Melphalan is an alkylating antineoplastic agent used in the treatment of several hematologic and solid tumours. - Multiple myeloma: induces remission and prolongs survival in eligible patients. - Ovarian cancer: incorporated into combination chemotherapy regimens to reduce tumour burden. - Malignant melanoma: administered as part of high‑dose therapy for metastatic disease. - Acute leukemia: used in induction protocols to achieve remission.

What are the side effects of Melphalan?

Melphalan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Myelosuppression - Fatigue - Alopecia

Serious or Rare Side Effects: - Secondary malignancies - Severe infection - Pulmonary toxicity

What precautions apply to Melphalan?

When using melphalan, careful monitoring and specific precautions are recommended. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess renal function: adjust therapy if impairment is present. - Evaluate hepatic function: monitor liver enzymes during treatment. - Avoid use in patients with known hypersensitivity to melphalan. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

What does Melphalan interact with?

Melphalan can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Other alkylating agents: additive bone marrow toxicity. - Concurrent radiotherapy: enhanced tissue damage. - Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampin): may reduce melphalan exposure. - Anticoagulants (warfarin): heightened bleeding risk. - NSAIDs: may exacerbate renal toxicity.

Frequently asked questions

What conditions is Melphalan used to treat?+
Melphalan is indicated for the treatment of multiple myeloma, ovarian cancer, malignant melanoma and acute leukemia. In each case it is used as part of a chemotherapy regimen designed to reduce tumour burden, achieve remission, or prolong survival under the supervision of an oncologist.
How does melphalan work in the body?+
Melphalan belongs to the alkylating‑agent class. It binds covalently to DNA, forming cross‑links that block replication and transcription. This DNA damage triggers cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells, while sparing most normal tissues.
What determines the dose of melphalan?+
The dose of melphalan is individualized by the prescribing physician based on factors such as the specific cancer type, disease stage, patient weight or body surface area, renal and hepatic function, and prior treatment history. No fixed dosing schedule is provided here.
Is melphalan safe during pregnancy or breastfeeding?+
Melphalan is classified as contraindicated in pregnancy and breastfeeding because it can cross the placenta and be excreted in breast milk, posing a risk to the fetus or infant. Use is only considered if the potential benefit outweighs the known risks, and only under specialist guidance.
How do I order Melphalan Sun Pharmaceutical from GNH USA?+
To request Melphalan Sun Pharmaceutical, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.
How does melphalan compare with other alkylating agents?+
Melphalan shares the core DNA‑cross‑linking mechanism of other alkylating agents but differs in its pharmacokinetic profile and approved indications. Compared with cyclophosphamide, melphalan is often preferred for high‑dose regimens in multiple myeloma and certain solid tumours, while it may have a higher risk of specific toxicities such as secondary malignancies.
What are the recommended storage conditions for melphalan?+
Melphalan for intravenous use should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept protected from light, moisture and extreme temperature fluctuations to maintain product stability.
How is melphalan administered to patients?+
Melphalan is administered intravenously by a qualified healthcare professional. The infusion is typically given over a defined period, often as a short‑term infusion or as part of a high‑dose protocol, depending on the treatment plan established by the oncologist.
What are the most serious risks associated with melphalan therapy?+
The most serious risks include secondary malignancies, severe infections due to profound myelosuppression, and organ‑specific toxicities such as pulmonary fibrosis or renal failure. Patients should be closely monitored for signs of infection, respiratory distress, and changes in kidney function throughout treatment.
Who should not receive melphalan?+
Melphalan is contraindicated in individuals with known hypersensitivity to the drug, in pregnant or breastfeeding women unless absolutely necessary, and in patients with severe uncontrolled infections or significant organ dysfunction that would increase toxicity risk. Final eligibility is determined by the treating physician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Melphalan
Route
Intravenous Use
Manufacturer
Sun Pharmaceutical Industries Europe B.V.
Origin
EU

Related products

Alkeran 2 mg

Alkeran 2 mg

Melphalan · 2 MG

Alkeran
TABLET
ASPEN PHARMACARE CANADA INC.
CANADA
Alkeran

Alkeran

Melphalan

Aspen Pharma Trading Limited
EU
Alkeran

Alkeran

Melphalan

Aspen Pharma Trading Limited
EU
Alkeran

Alkeran

Melphalan

Aspen Pharma Trading Limited
EU